Qorvo Biotechnologies

Qorvo Biotechnologies is a diagnostics company that utilizes advanced semiconductor technology to provide high-sensitivity point-of-care (POC) testing. The company's proprietary platform is based on Bulk Acoustic Wave (BAW) sensors, which enable the detection of low-level biomarkers and pathogens with lab-quality precision in a portable format. Originally developed as a division of the semiconductor leader Qorvo Inc., the business was acquired by Zoetis in 2023 to expand its portfolio of veterinary diagnostic tools. The platform's versatility allows for applications in both human and animal health, including respiratory infections and cardiac health monitoring. Their flagship product, the Qorvo Omnia platform, received FDA Emergency Use Authorization for COVID-19 testing during the pandemic. The technology represents a significant shift in POC diagnostics by bringing the sensitivity of central laboratory immunoassay systems to the near-patient setting.